Skip to main content
. 2021 Oct 28;8:724373. doi: 10.3389/fmolb.2021.724373

FIGURE 4.

FIGURE 4

Serum and exosomal BATF2 downregulation as an indicator for monitoring efficacy and recurrence in NPC. of Serum (A,B) and exosomal (C,D) BATF2 mRNA expressions in NPC patients at baseline, after treatment (radiotherapy or chemotherapy or targeted therapy), at the diagnosis of recurrent NPC. ROC curves of serum (E) and exosomal (F) BATF2 mRNA expressions in predicting the relaps eof NPC. (G,H) Serum BATF2 mRNA expression level in two NPC patients participating in the follow-up during radiotherapy or chemotherapy or targeted therapy. **p < 0.01.